FGF-21, Liver Fat, and Belly Fat: What’s Really Driving Metabolic Health?

A 12-week clinical trial reveals that GLS—a 2:1 blend of Coptidis Rhizoma and Evodiae Fructus—may significantly reduce liver fat and improve metabolic markers in adults with nonalcoholic fatty liver disease (NAFLD). When combined with lifestyle changes, GLS led to a striking 35.6 dB/m reduction in hepatic fat (measured by CAP), far outpacing the 20.8 dB/m drop seen with polyene phosphatidylcholine, a common liver support supplement.

Participants also experienced greater reductions in liver enzymes—ALT, AST, and GGT—suggesting a stronger hepatoprotective effect. The average ALT drop was 39.4 U/L with GLS versus 30.0 U/L in the control group. These findings point to GLS not just as a supportive agent, but as a potentially active therapeutic in reversing early-stage fatty liver.

While the study is open-label and lacks a placebo, its high pro score (63.0) reflects strong internal consistency and clinical relevance. The formula’s traditional use in Chinese medicine may now be gaining modern validation.

Emerging data suggest that serum fibroblast growth factor 21 (FGF-21) may serve as a dynamic biomarker for metabolic and liver health. In NAFLD patients taking GLS for 12 weeks, reductions in FGF-21 levels were positively correlated with improvements in both gamma-glutamyl transferase (r = 0.374) and waist circumference (r = 0.343). This implies that as metabolic stress decreases, the body may downregulate FGF-21 production—a hormone typically elevated in insulin resistance and fatty liver.

Interestingly, the GLS group saw a mean FGF-21 drop of 32.0 pg/mL, compared to 23.5 pg/mL in the control group. This supports the idea that effective interventions reduce the need for compensatory FGF-21 secretion.

While FGF-21 was once seen only as a therapeutic target, these findings flip the script: lower levels may now signal improvement, not dysfunction. This could reshape how we monitor treatment response in metabolic diseases.

Beyond liver fat, the herbal compound GLS appears to target central adiposity—a key driver of metabolic risk. In the same 12-week trial, patients taking GLS lost an average of 3.45 kg, compared to 1.95 kg in the control group. Waist circumference and waist-to-hip ratio also improved more significantly, indicating a preferential loss of visceral fat.

These changes align with broader metabolic improvements, including better insulin sensitivity and lipid profiles, though the exact mechanisms remain under study. The synergy between GLS and lifestyle intervention suggests it may enhance the body’s response to diet and exercise.

While more rigorous trials are needed, the consistency of results across multiple endpoints—liver fat, enzymes, weight, and FGF-21—lends credibility to GLS as a multi-system metabolic modulator.

A year-long study compared an Asian ketogenic diet (AKD)—low-carb, high-fat, with increased whole egg intake—to a balanced low-calorie diet (BLC) in adults with metabolic syndrome. The AKD group showed superior improvements in HbA1c, triglycerides, HDL cholesterol, and waist circumference.

Despite cultural dietary patterns often being higher in carbohydrates, this tailored low-carb approach proved sustainable and effective. Participants reported high adherence, possibly due to the inclusion of familiar foods like eggs, fish, and non-starchy vegetables.

Key outcomes included:

• Greater reduction in fasting insulin
• Improved liver enzymes
• Sustained weight loss without muscle loss

This suggests that low-carb diets can be successfully adapted to diverse cultural contexts.

A viral fitness video claims that a certain unnamed hormone is 'worse than cortisol' for driving belly fat—and shockingly, that exercise can make it worse. While cortisol is well-known for promoting visceral fat under chronic stress, the video offers no clear identification or mechanism for this alleged 'worse' hormone.

The claim scored 27.0 (Pro) to 5.0 (Against), indicating some engagement but no scientific summary or citation. Without specifics, it’s impossible to evaluate whether this refers to insulin, leptin, or another metabolic signal.

Exercise, despite acute hormonal fluctuations, remains a cornerstone of fat loss and metabolic health. Blanket statements that 'exercise makes belly fat worse' contradict decades of evidence and should be treated with skepticism.